Clinical Trial

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least two lines of chemotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-03.
Status change: Not Yet Recruiting → Recruiting 2025-02-06
Trial Details
NCT Number NCT06629597
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions Nasopharyngeal Carcinoma
Enrollment 400 participants
Start Date 2024-12-31
Primary Completion 2027-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-10